Madrigal Pharmaceuticals Q3 2024 GAAP EPS $(4.92) Beats $(6.92) Estimate, Sales $62.175M Beat $33.656M Estimate
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals reported better-than-expected Q3 2024 results, with a GAAP EPS of $(4.92) beating the estimate of $(6.92) and sales of $62.175 million surpassing the $33.656 million estimate.
October 31, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals reported a Q3 2024 GAAP EPS of $(4.92), beating the estimate of $(6.92), and sales of $62.175 million, exceeding the $33.656 million estimate.
Madrigal Pharmaceuticals' better-than-expected earnings and sales figures are likely to positively impact its stock price in the short term. The significant beat on both EPS and sales indicates strong performance, which is typically viewed favorably by investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100